MCID: BRD004
MIFTS: 49

Borderline Personality Disorder

Categories: Mental diseases

Aliases & Classifications for Borderline Personality Disorder

MalaCards integrated aliases for Borderline Personality Disorder:

Name: Borderline Personality Disorder 12 76 55 44 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:10930
ICD10 33 F60.3
ICD9CM 35 301.83
MeSH 44 D001883
NCIt 50 C92633
SNOMED-CT 68 192488005 20010003
UMLS 73 C0006012

Summaries for Borderline Personality Disorder

Disease Ontology : 12 A personality disorder that involves a prolonged disturbance of personality function characterized by depth and variability of moods.

MalaCards based summary : Borderline Personality Disorder is related to alexithymia and intermittent explosive disorder. An important gene associated with Borderline Personality Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Neuroscience and Circadian rythm related genes. The drugs Citalopram and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, amygdala and bone, and related phenotypes are behavior/neurological and homeostasis/metabolism

Wikipedia : 76 Borderline personality disorder (BPD), also known as emotionally unstable personality disorder (EUPD),... more...

Related Diseases for Borderline Personality Disorder

Diseases related to Borderline Personality Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 alexithymia 30.8 COMT HTR1A SLC6A4
2 intermittent explosive disorder 30.2 HTR1A SLC6A4
3 antisocial personality disorder 30.1 COMT HTR1B MAOA SLC6A4
4 conduct disorder 30.1 COMT MAOA SLC6A4 TPH1
5 social phobia 30.1 HTR1A MAOA SLC6A4
6 substance dependence 30.1 BDNF HTR1B MAOA SLC6A4
7 dysthymic disorder 30.0 HTR2A MAOA SLC6A4
8 eating disorder 29.9 BDNF COMT HTR2C SLC6A4
9 anorexia nervosa 29.8 BDNF COMT HTR2A SLC6A4
10 schizoaffective disorder 29.6 BDNF COMT HTR2A SLC6A4
11 oppositional defiant disorder 29.4 COMT MAOA SLC6A4 TPH2
12 substance abuse 29.2 BDNF COMT HTR1B MAOA SLC6A4
13 bulimia nervosa 29.1 BDNF COMT HTR1B HTR2A MAOA SLC6A4
14 generalized anxiety disorder 28.5 BDNF HTR1A HTR2A MAOA SLC6A4 TPH1
15 bipolar i disorder 28.4 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
16 personality disorder 27.7 BDNF COMT HTR1A HTR1B HTR2A HTR2C
17 psychotic disorder 27.7 BDNF COMT HTR1A HTR2A HTR2C SLC6A4
18 disease of mental health 27.6 BDNF COMT HTR1A HTR2A HTR2C MAOA
19 post-traumatic stress disorder 27.5 BDNF COMT FKBP5 HTR2A MAOA NR3C1
20 depression 26.9 BDNF HTR1A HTR2A HTR2C MAOA NR3C1
21 attention deficit-hyperactivity disorder 26.4 BDNF COMT HTR1A HTR1B HTR2A HTR2C
22 panic disorder 26.3 BDNF COMT HTR1A HTR2A HTR2C MAOA
23 bipolar disorder 26.1 BDNF COMT HTR1A HTR2A HTR2C MAOA
24 schizophrenia 26.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
25 anxiety 25.8 BDNF COMT HTR1A HTR2A HTR2C MAOA
26 mood disorder 25.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
27 major depressive disorder 24.3 BDNF COMT FKBP5 HTR1A HTR1B HTR2A
28 alcohol dependence 24.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C
29 multiple personality disorder 11.2
30 impulse control disorder 10.9
31 alzheimer disease 5 10.6 HTR2A SLC6A4
32 atypical depressive disorder 10.6 MAOA SLC6A4
33 phobia, specific 10.6 COMT MAOA
34 alcoholic psychosis 10.5 HTR2A SLC6A4
35 tardive dyskinesia 10.5 COMT HTR2A
36 schizoid personality disorder 10.5 HTR1A HTR2A
37 hypoactive sexual desire disorder 10.5 HTR1A HTR2A
38 substance-induced psychosis 10.5 HTR1A HTR2A
39 bruxism 10.4 HTR2A SLC6A4
40 autoimmune polyendocrine syndrome type 1 10.4 TPH1 TPH2
41 drug-induced mental disorder 10.4 HTR1A HTR2A
42 drug psychosis 10.4 HTR1A HTR2A
43 dystonia 1, torsion, autosomal dominant 10.4 COMT MAOA
44 specific developmental disorder 10.4 BDNF COMT SLC6A4
45 endogenous depression 10.3 BDNF MAOA SLC6A4
46 traumatic brain injury 10.3 BDNF COMT
47 kleptomania 10.3 HTR1A MAOA SLC6A4
48 fibromyalgia 10.3 COMT HTR2A SLC6A4
49 agoraphobia 10.3 HTR1A MAOA SLC6A4
50 pathological gambling 10.3 HTR2A MAOA SLC6A4

Comorbidity relations with Borderline Personality Disorder via Phenotypic Disease Network (PDN):


Acute Cystitis Anxiety
Cerebral Atherosclerosis Dependent Personality Disorder
Dysthymic Disorder Hypertension, Essential
Hypothyroidism Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Borderline Personality Disorder:



Diseases related to Borderline Personality Disorder

Symptoms & Phenotypes for Borderline Personality Disorder

MGI Mouse Phenotypes related to Borderline Personality Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.15 HTR1A HTR1B TPH1 HTR2A HTR2C TPH2
2 homeostasis/metabolism MP:0005376 9.96 SLC6A4 HTR1A TPH1 HTR2C TPH2 MAOA
3 cardiovascular system MP:0005385 9.92 SLC6A4 HTR1A HTR1B TPH1 TPH2 MAOA
4 adipose tissue MP:0005375 9.8 HTR1B TPH1 HTR2C TPH2 NR3C1
5 integument MP:0010771 9.63 SLC6A4 TPH1 HTR2C TPH2 BDNF NR3C1
6 muscle MP:0005369 9.43 SLC6A4 HTR1B TPH1 HTR2A HTR2C NR3C1
7 nervous system MP:0003631 9.23 SLC6A4 HTR1A HTR2C TPH2 MAOA BDNF

Drugs & Therapeutics for Borderline Personality Disorder

Drugs for Borderline Personality Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 120)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Citalopram Approved Phase 4,Phase 2,Not Applicable 59729-33-8 2771
2
Dopamine Approved Phase 4,Phase 2,Not Applicable 51-61-6, 62-31-7 681
3
Risperidone Approved, Investigational Phase 4,Not Applicable 106266-06-2 5073
4
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
5
Fluoxetine Approved, Vet_approved Phase 4 54910-89-3 3386
6 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
7 Antidepressive Agents Phase 4,Phase 2,Not Applicable
8 Antidepressive Agents, Second-Generation Phase 4,Phase 2,Not Applicable
9 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
10 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
11 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
14 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
15 Cholinergic Agents Phase 4,Phase 2,Not Applicable
16 Cholinergic Antagonists Phase 4,Phase 2,Not Applicable
17 Muscarinic Antagonists Phase 4,Phase 2,Not Applicable
18 Parasympatholytics Phase 4,Phase 2,Not Applicable
19 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
20 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
22 Dopamine Agents Phase 4,Phase 2,Not Applicable
23 Dopamine Antagonists Phase 4,Phase 2,Not Applicable
24 Serotonin Antagonists Phase 4,Phase 2,Not Applicable
25 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Anticonvulsants Phase 4,Phase 3,Not Applicable
27 calcium channel blockers Phase 4
28 Calcium, Dietary Phase 4
29 Diuretics, Potassium Sparing Phase 4
30 Excitatory Amino Acid Antagonists Phase 4,Phase 2
31 Excitatory Amino Acids Phase 4,Phase 2
32 Sodium Channel Blockers Phase 4
33 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
34 Cytochrome P-450 Enzyme Inhibitors Phase 4
35 Omega 3 Fatty Acid Nutraceutical Phase 4
36
Serotonin Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
37
Naltrexone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 16590-41-3 5360515
38
Ethanol Approved Phase 3,Phase 2,Not Applicable 64-17-5 702
39
Selegiline Approved, Investigational, Vet_approved Phase 3 14611-51-9 26757 5195
40
Olanzapine Approved, Investigational Phase 3,Not Applicable 132539-06-1 4585
41 Narcotic Antagonists Phase 3,Phase 2,Not Applicable
42 Narcotics Phase 3,Phase 2,Not Applicable
43 Quetiapine Fumarate Phase 3,Phase 2 111974-72-2
44 Antiemetics Phase 3,Not Applicable
45 Gastrointestinal Agents Phase 3,Not Applicable
46 Anti-Infective Agents Phase 3,Phase 2,Phase 1
47 Anti-Infective Agents, Local Phase 3,Phase 2
48 Protective Agents Phase 3,Phase 2,Phase 1
49
Acetaminophen Approved Phase 2 103-90-2 1983
50
Ziprasidone Approved Phase 2 146939-27-7 60854

Interventional clinical trials:

(show top 50) (show all 148)
# Name Status NCT ID Phase Drugs
1 Efficacy of Omega-3 Fatty Acids on Borderline Personality Disorder Unknown status NCT00437099 Phase 4 Omacor®;Placebo
2 Study of Lamotrigine Treatment of Affective Instability in Borderline Personality Disorder Completed NCT00634062 Phase 4 Lamotrigine;Placebo
3 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed NCT00533117 Phase 4 Fluoxetine
4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed NCT00834834 Phase 4 Fluoxetine;Citalopram
5 Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder Completed NCT00204347 Phase 4 risperidone
6 Effects of Comorbid Personality Disorder on the Treatment of Bipolar I Disorder Completed NCT00178061 Phase 4
7 BOSCOT : A Randomised Controlled Trial of Cognitive Behavioural Therapy in Borderline Personality Disorder Completed NCT00538135 Phase 3
8 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed NCT00880919 Phase 3 quetiapine extended-release;Placebo
9 Clinical Research Study to Evaluate Selegiline in the Treatment of Borderline Personality Disorder Completed NCT01912391 Phase 3 Selegiline;Placebo (for Selegiline)
10 Quetiapine Treatment for Symptoms Associated With Borderline Personality Disorder Completed NCT00122070 Phase 3 Quetiapine Fumarate
11 Olanzapine in Patients With Borderline Personality Disorder Completed NCT00091650 Phase 3 Olanzapine;placebo
12 Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder Completed NCT00088036 Phase 3 Olanzapine
13 Naltrexone in Borderline Personality Disorder Terminated NCT00124839 Phase 3 Naltrexone
14 Topiramate for Treatment of Patients With Borderline Personality Disorder and Alcohol Dependence Withdrawn NCT00463775 Phase 3 Topiramate
15 Acetaminophen and Social Processes Unknown status NCT02108990 Phase 2 Acetaminophen
16 Central Meditation and Imagery Therapy for Augmentation of Borderline Personality Disorder Treatment Completed NCT02125942 Phase 1, Phase 2
17 Ziprasidone in the Treatment of Borderline Personality Disorder Completed NCT00635921 Phase 2 ziprasidone;Placebo
18 Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder Completed NCT01103180 Phase 2 Escitalopram
19 Verkes Borderline Study: The Effect of Quetiapine on Borderline Personality Disordered Patients Completed NCT00254748 Phase 2 Quetiapine fumarate;Placebo
20 Psychodynamic Therapy For Co-occurring Borderline Personality Disorder and Alcohol Use Disorder Completed NCT00145678 Phase 2
21 Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder Completed NCT01133301 Phase 2 Naltrexone;Placebo
22 Treating PTSD in Patients With Borderline Personality Disorder Completed NCT01081314 Phase 1, Phase 2
23 Treatment of Suicidal Women With Borderline Personality Disorder Completed NCT00183651 Phase 2
24 Oxytocin as Adjunctive Therapy for Schizophrenia Completed NCT01699997 Phase 2 Oxytocin;Placebo
25 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed NCT01189812 Phase 2 Lithium Carbonate;Placebo;Citalopram
26 Cognitive Therapy for PTSD in Addiction Treatment Completed NCT00685451 Phase 1, Phase 2
27 A Novel Drug for Borderline Personality Disorder Recruiting NCT02097706 Phase 2 NMDA receptor antagonist (active drug)
28 Botulinum Toxin A for Emotional Stabilization in Borderline Personality Disorder (BPD) Recruiting NCT02728778 Phase 2 incobotulinumtoxin A
29 Ketamine in Borderline Personality Disorder Recruiting NCT03395314 Phase 2 Ketamine;Midazolam
30 Preliminary Trial of the Effect of Glucocorticoid Receptor Antagonist on Borderline Personality Disorder (BPD) Recruiting NCT01212588 Phase 2 mifepristone;Placebo
31 Oxytocin on Irritability/Emotional Dysregulation of Disruptive Behavior and Mood Disorders Recruiting NCT02824627 Phase 2 Oxytocin;Placebo
32 Brexpiprazole in Borderline Personality Disorder Not yet recruiting NCT03418675 Phase 2 Rexulti;Placebo
33 Emotional Regulation and Impulsivity Among Adolescents With Borderline Personality Disorder Not yet recruiting NCT03209102 Phase 2
34 N-Acetylcysteine in Adjunct to DBT for the Treatment of Self-Injurious Behavior in BPD Terminated NCT00539188 Phase 2 N-Acetylcysteine;placebo
35 Creativity Group for Borderline Personality Disorder Unknown status NCT01343550 Phase 1
36 Outcome of Crisis Intervention for Subjects With Borderline Personality Disorder or Post-Traumatic Stress Disorder Unknown status NCT00269139 Phase 1
37 20 Weeks DBT Group Skills Training Study Completed NCT01193205 Phase 1
38 Early Study of N-Acetylcysteine to Treat Deliberate Self-Harm in Adolescents Completed NCT01111734 Phase 1 fMRI
39 Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations Recruiting NCT02149823 Phase 1 Syntocinon 24 Intranasal Units (IU);Syntocinon 40 Intranasal Units (IU);Intranasal Placebo
40 Trial of Effect of High-frequency Transcranial Magnetic Stimulation in the Management of Borderline Personality Disorder Unknown status NCT01602497 Not Applicable
41 Event Related Potentials in Borderline Personality Disorder and Major Depression Unknown status NCT01469663
42 CPT Group for DBT Clients With Co-Occurring Borderline Personality Disorder and PTSD Unknown status NCT02574429 Not Applicable
43 Promoting Recovery Processes in Women With Borderline Personality Disorder Using a Dynamic Cognitive Intervention Unknown status NCT01531634 Not Applicable
44 Guanfacine to Treat Borderline Personality Disorder Unknown status NCT00358969 Not Applicable guanfacine (Tenex)
45 A Randomized Control Trial of Narrative Exposure Therapy Versus Treatment as Usual in the Therapy of Borderline Personality Disorder Unknown status NCT01033708 Not Applicable
46 Cognitive Therapy Versus Supportive Therapy in Borderline Personality Disorder Unknown status NCT00131781 Not Applicable
47 A Double Blind Crossover Study on the Effect of MPH on Decision-making Ability of Adults With BPD Compared to Adults With ADHD and Healthy Adults Unknown status NCT01426984 Not Applicable methylphenidate
48 DBT in Borderline Personality Disorder Unknown status NCT00252031 Not Applicable
49 DBT and Escitalopram in Borderline Personality Disorder Unknown status NCT00255554 Not Applicable Escitalopram
50 Nalmefene in Alcohol Dependence and Borderline Personality Disorder Unknown status NCT02752503 Not Applicable Nalmefene

Search NIH Clinical Center for Borderline Personality Disorder

Cochrane evidence based reviews: borderline personality disorder

Genetic Tests for Borderline Personality Disorder

Anatomical Context for Borderline Personality Disorder

MalaCards organs/tissues related to Borderline Personality Disorder:

41
Brain, Amygdala, Bone, Testes, Pituitary, Ovary, Cortex

Publications for Borderline Personality Disorder

Articles related to Borderline Personality Disorder:

(show top 50) (show all 786)
# Title Authors Year
1
Exclusion-Proneness in Borderline Personality Disorder Inpatients Impairs Alliance in Mentalization-Based Group Therapy. ( 29910754 )
2018
2
Change in Biased Thinking in a Treatment Based on the Motive-Oriented Therapeutic Relationship for Borderline Personality Disorder. ( 29388899 )
2018
3
Positive psychotic symptoms in patients with borderline personality disorder: a valuable but still not completely understood clinical marker of the illness. ( 29873564 )
2018
4
The effect of methylphenidate on decision making in patients with borderline personality disorder and attention-deficit/hyperactivity disorder. ( 29847836 )
2018
5
Individuals with Borderline Personality Disorder manifest cognitive biases implicated in psychosis. ( 29960939 )
2018
6
Sensitization of the Neural Salience Network to Repeated Emotional Stimuli Following Initial Habituation in Patients With Borderline Personality Disorder. ( 29961363 )
2018
7
Training in Good Psychiatric Management for Borderline Personality Disorder in Residency: An Aide to Learning Supportive Psychotherapy for Challenging-to-Treat Patients. ( 29809114 )
2018
8
On the potential for iatrogenic effects of psychiatric crisis services: The example of dialectical behavior therapy for adult women with borderline personality disorder. ( 29369662 )
2018
9
Erratum - Borderline Personality Disorder Symptom Severity and Sexually Transmitted Infection and HIV Risk in African American Incarcerated Men. ( 29889162 )
2018
10
Borderline personality disorder is equally trait-like and state-like over ten years in adult psychiatric patients. ( 29952598 )
2018
11
Behavioural mimicry and loneliness in borderline personality disorder. ( 29407356 )
2018
12
The Endocannabinoid System, Aggression, and the Violence of Synthetic Cannabinoid Use, Borderline Personality Disorder, Antisocial Personality Disorder, and Other Psychiatric Disorders. ( 29636670 )
2018
13
Variability in phase and amplitude of diurnal rhythms is related to variation of mood in bipolar and borderline personality disorder. ( 29374207 )
2018
14
Abnormal Sensitization of Neural and Behavioral Responses to Socially Relevant Images in Individuals With Borderline Personality Disorder: Implications for Guiding More Effective Targeting of Treatments. ( 29961366 )
2018
15
Psychosocial stress differentially affects emotional empathy in women with borderline personality disorder and healthy controls. ( 29417987 )
2018
16
Differential relations of executive functioning to borderline personality disorder presentations in adolescents. ( 29388349 )
2018
17
Transient hallucinations during interpersonal stress in an adolescent with borderline personality disorder. ( 29374970 )
2018
18
Perimenstrual exacerbation of symptoms in borderline personality disorder: evidence from multilevel models and the Carolina Premenstrual Assessment Scoring System. ( 29860953 )
2018
19
Dissecting the elements of borderline personality disorder. ( 29878704 )
2018
20
Fear of Being Laughed at in Borderline Personality Disorder. ( 29410640 )
2018
21
Alliance Rupture and Resolution in Dialectical Behavior Therapy for Borderline Personality Disorder. ( 29388901 )
2018
22
Improving functional outcomes in women with borderline personality disorder and PTSD by changing PTSD severity and post-traumatic cognitions. ( 29448136 )
2018
23
Borderline personality disorder and sexual abuse: A systematic review. ( 29407572 )
2018
24
Psychiatrists' motives for practising in-patient compulsory care of patients with borderline personality disorder (BPD). ( 29853014 )
2018
25
Features of borderline personality disorder as a mediator of the relation between childhood traumatic experiences and psychosis-like experiences in patients with mood disorder. ( 29353179 )
2018
26
Clinical Components of Borderline Personality Disorder and Personality Functioning. ( 29393279 )
2018
27
Treatment of a Patient with Borderline Personality Disorder Based on Phase-Oriented Model of Eye Movement Desensitization and Reprocessing (EMDR): A Case Report. ( 29892320 )
2018
28
The Role of Negative Affect and Self-Concept Clarity in Predicting Self-Injurious Urges in Borderline Personality Disorder Using Ecological Momentary Assessment. ( 29388895 )
2018
29
Construct Validity of the McLean Screening Instrument for Borderline Personality Disorder in Two Singaporean Samples. ( 29949444 )
2018
30
Reduced white matter integrity in borderline personality disorder: A diffusion tensor imaging study. ( 28922736 )
2018
31
Partners of Individuals with Borderline Personality Disorder: A Systematic Review of the Literature Examining Their Experiences and the Supports Available to Them. ( 29975337 )
2018
32
Emotional responses to receiving peer feedback on opinions in borderline personality disorder. ( 29927294 )
2018
33
The rewarding nature of provocation-focused rumination in women with borderline personality disorder: a preliminary fMRI investigation. ( 29372058 )
2018
34
Book Review: Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods Integrated Modular Treatment for Borderline Personality Disorder: A Practical Guide to Combining Effective Treatment Methods . Livesley W. John . Cambridge (UK) : Cambridge University Press ; 2017 . 297 p. US$66.50 . Paperback. ISBN 978-1-10-67974-0 . Reviewer rating: Excellent. ( 29433334 )
2018
35
Mentalization-Based Treatment for Concurrent Borderline Personality Disorder and Substance Use Disorder: A Randomized Controlled Feasibility Study. ( 29402870 )
2018
36
Symptom, alexithymia and self-image outcomes of Mentalisation-based treatment for borderline personality disorder: a naturalistic study. ( 29890960 )
2018
37
Assessing advanced theory of mind and alexithymia in patients suffering from enduring borderline personality disorder. ( 29360051 )
2018
38
Men and women with borderline personality disorder resident in Dutch special psychiatric units in prisons: A descriptive and comparative study. ( 29971844 )
2018
39
Treating borderline personality disorder with oxytocin: An enthusiastic note of caution. Commentary to Servan et al. The effect of oxytocin in borderline personality disorder. ( 29402386 )
2018
40
Affect dysregulation, psychoform dissociation, and adult relational fears mediate the relationship between childhood trauma and complex posttraumatic stress disorder independent of the symptoms of borderline personality disorder. ( 29410773 )
2018
41
Borderline personality disorder features and drinking, cannabis, and prescription opioid motives: Differential associations across substance and sex. ( 29945027 )
2018
42
Attachment-Related Regulatory Processes Moderate the Impact of Adverse Childhood Experiences on Stress Reaction in Borderline Personality Disorder. ( 29388902 )
2018
43
Opioid addiction and borderline personality disorder. ( 29283477 )
2018
44
Estimating the prevalence of borderline personality disorder in mothers involved in youth protection services. ( 28944592 )
2017
45
Pain Perception and Body Awareness Among Individuals With Borderline Personality Disorder. ( 28902571 )
2017
46
People with Borderline Personality Disorder and Burns: Some Considerations for Health Professionals. ( 28945490 )
2017
47
A prospective, longitudinal, study of men with borderline personality disorder with and without comorbid antisocial personality disorder. ( 29225887 )
2017
48
Interpersonal Threat Sensitivity in Borderline Personality Disorder: An Eye-Tracking Study. ( 28072041 )
2017
49
Determining if Borderline Personality Disorder and Bipolar Disorder Are Alternative Expressions of the Same Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions. ( 28922592 )
2017
50
A Mother's Borderline Personality Disorder and Her Sensitivity, Autonomy Support, Hostility, Fearful/Disoriented Behavior, and Role Reversal With Her Young Child. ( 28072039 )
2017

Variations for Borderline Personality Disorder

Expression for Borderline Personality Disorder

Search GEO for disease gene expression data for Borderline Personality Disorder.

Pathways for Borderline Personality Disorder

Pathways related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1 12.27 COMT HTR1A TPH1 TPH2
3
Show member pathways
12.02 BDNF HTR1A HTR1B
4 11.97 BDNF HTR1A HTR2A MAOA NR3C1 SLC6A4
5
Show member pathways
11.93 MAOA TPH1 TPH2
6
Show member pathways
11.68 HTR1A HTR1B HTR2A HTR2C
7 11.61 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
8
Show member pathways
11.21 MAOA SLC6A4 TPH2
9
Show member pathways
11.16 TPH1 TPH2
10
Show member pathways
10.99 TPH1 TPH2
11
Show member pathways
10.96 COMT MAOA SLC6A4
12 10.8 HTR2A HTR2C
13
Show member pathways
10.78 COMT MAOA TPH1
14 10.67 HTR1A HTR1B HTR2A HTR2C MAOA SLC6A4
15
Show member pathways
10.65 COMT MAOA
16 10.6 COMT MAOA

GO Terms for Borderline Personality Disorder

Cellular components related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.43 HTR1A HTR1B HTR2A HTR2C NRXN3 SLC6A4
2 dendrite GO:0030425 9.1 BDNF COMT HTR1A HTR1B HTR2A HTR2C

Biological processes related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.83 COMT HTR1B HTR2A HTR2C SLC6A4
2 circadian rhythm GO:0007623 9.77 SLC6A4 TPH1 TPH2
3 chemical synaptic transmission GO:0007268 9.77 HTR1A HTR1B HTR2A HTR2C NRXN3
4 memory GO:0007613 9.73 BDNF HTR2A SLC6A4
5 positive regulation of fat cell differentiation GO:0045600 9.7 HTR2A HTR2C TPH1
6 release of sequestered calcium ion into cytosol GO:0051209 9.63 HTR2A HTR2C
7 behavioral fear response GO:0001662 9.62 HTR1A HTR2C
8 regulation of dopamine secretion GO:0014059 9.62 HTR1B HTR2A
9 bone remodeling GO:0046849 9.61 HTR1B TPH1
10 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.61 HTR1B HTR2A
11 neurotransmitter catabolic process GO:0042135 9.59 COMT MAOA
12 catecholamine metabolic process GO:0006584 9.58 COMT MAOA
13 aromatic amino acid family metabolic process GO:0009072 9.58 TPH1 TPH2
14 G-protein coupled serotonin receptor signaling pathway GO:0098664 9.58 HTR1A HTR1B HTR2A
15 dopamine catabolic process GO:0042420 9.57 COMT MAOA
16 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.56 HTR1A HTR1B HTR2A HTR2C
17 regulation of hormone secretion GO:0046883 9.55 HTR1A HTR2A
18 indolalkylamine biosynthetic process GO:0046219 9.54 TPH1 TPH2
19 adenylate cyclase-inhibiting serotonin receptor signaling pathway GO:0007198 9.51 HTR1A HTR1B
20 vasoconstriction GO:0042310 9.5 HTR1A HTR1B SLC6A4
21 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.49 HTR2A HTR2C
22 serotonin biosynthetic process GO:0042427 9.48 TPH1 TPH2
23 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.46 HTR2A HTR2C
24 regulation of behavior GO:0050795 9.33 HTR1A HTR1B HTR2A
25 serotonin receptor signaling pathway GO:0007210 9.13 HTR1A HTR2A HTR2C
26 behavior GO:0007610 8.92 HTR1A HTR1B HTR2A HTR2C

Molecular functions related to Borderline Personality Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 obsolete signal transducer activity GO:0004871 9.73 HTR1A HTR1B HTR2A HTR2C
2 drug binding GO:0008144 9.58 HTR1B HTR2A HTR2C
3 neurotransmitter receptor activity GO:0030594 9.46 HTR1A HTR1B HTR2A HTR2C
4 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced pteridine as one donor, and incorporation of one atom of oxygen GO:0016714 9.37 TPH1 TPH2
5 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 9.32 HTR2A HTR2C
6 tryptophan 5-monooxygenase activity GO:0004510 9.26 TPH1 TPH2
7 G-protein coupled serotonin receptor activity GO:0004993 9.26 HTR1A HTR1B HTR2A HTR2C
8 serotonin binding GO:0051378 8.92 HTR1A HTR1B HTR2A HTR2C

Sources for Borderline Personality Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....